InxMed

InxMed, founded in 2018, is a cutting-edge biotechnology company in the global clinical research and development stage. The company focuses on innovative drug development to overcome resistance and metastasis in solid tumors that lack effective treatment options. With translational medicine as its source of innovation, the company leverages its robust clinical capabilities to build an efficient platform from disease biology mechanism research, innovative drug discovery, to clinical translation and proof-of-concept, aiming to become a global leader in revolutionary cancer therapies. InxMed has established teams in Shanghai, Beijing, and Nanjing in China, and possesses a high-level translational medicine and clinical development team spanning across China, the United States, Canada, and Australia. Through independent innovation, product introduction, and co-development, the company has built a unique and effective global R&D pipeline, committed to achieving "First in Class" and "Best in Class." InxMed has formed partnerships with many multinational pharmaceutical companies, including Merck, Roche, and Boehringer Ingelheim, as well as domestic and international biotech firms. We actively seek opportunities for product introduction and co-development to maximize and optimize our product portfolio, bringing tangible clinical benefits to patients. The core team of the company has held senior R&D and management positions at top multinational pharmaceutical companies such as Roche, Novartis, Merck, Schering Plough, GSK, Johnson & Johnson, and Beigene. They have extensive experience in all aspects of innovative drug research, development, clinical translation, proof-of-concept, and product launch, having led the clinical development and registration of more than ten drugs in China, including Keytruda and Gardasil.